Same Indication

Montelukast vs Pembrolizumab

Montelukast vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Montelukast and Pembrolizumab.

Mechanism of Action

Montelukast: Selective leukotriene D4 receptor antagonist.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Montelukast — 2.7-5.5 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S.

Molecular Weight: Montelukast — 586.1800 g/mol.

Type: Montelukast — Small molecule; Pembrolizumab — Antibody.